新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 自身免疫性疾病 » 药明康德联手阿斯利康抢占中国风湿性关节炎市场

药明康德联手阿斯利康抢占中国风湿性关节炎市场

来源:生物谷 2015-04-08 09:10

2015年4月7日讯 /生物谷BIOON/ --随着欧美医药市场的饱和,越来越多的生物医药巨头开始把目光投向了以中国为代表的新兴市场。诺华、辉瑞等生物医药巨头早已经在中国做出自己的布局。中国有句老话--强龙不压地头蛇。要迅速进入这个庞大的市场,最好的方法莫过于和中国本土生物医药公司展开合作,这也是制药巨头阿斯利康公司的策略。

最近,药明康德公司和阿斯利康旗下Medlmmune公司公布了双方共同开发的治疗风湿性关节炎IL-7单抗药物MEDI5117在中国上市申请的时间表。MEDI5117是阿斯利康公司专门为中国市场设计的IL-7单抗药物。药明康德公司和Medlmmune公司双方对这一药物享有同等权利,不过,中国CFDA批准MEDI5117上市后,Medlmmune会享有优先收购药明康德手中股份的权利。目前双方已经于去年十二月向CFDA提交这一药物的上市申请,预计CFDA将于今年年底做出最终决定。

作为目前国内最大的CRO企业之一,药明康德也希望抓住这次难得的机遇,扩大公司在海内外的影响力。近年来,药明康德公司逐渐不再满足于单一的CRO业务,而是选择在中国医药市场上深耕细作。立足于广阔的中国市场,药明康德希望将自己打造为所有跨国医药公司进入中国市场的首选合作伙伴!此次与阿斯利康公司的合作无疑也使药明康德距实现这一愿望又近一步。

与此同时,药明康德公司2015年的营收预计将在7亿9千万美元-8亿美元之间,比2014年增长了18%。而为了完成这一目标,药明康德公司计划今年花费两亿美元用于资本运作,规模是去年的两倍,这其中就包括扩大公司的药物生产设施和扩大公司的基因组学业务。(生物谷Bioon.com)

详细英文报道:

Partners WuXi PharmaTech ($WX) and AstraZeneca's ($AZN) MedImmune are on schedule with a rheumatoid arthritis-treating antibody designed for the Chinese market, as the country's regulators have accepted their application.

The injection, MEDI5117, is an interleukin-7 antibody designed to tamp down the inflammation at the heart of autoimmune diseases like arthritis. The pair are developing the drug through a joint venture launched in 2012, maintaining equal ownership until the drug reaches the market, at which point AZ would have the option to buy out its partner. The JV submitted MEDI5117 to the Chinese FDA in December, and, with the application's acceptance, WuXi and MedImmune expect to get a final decision this year.

AstraZeneca cut the cord on an osteoarthritic pain program for MEDI5117 last year but preserved the antibody's Chinese ambitions, relying on WuXi to handle development and manufacturing.

MEDI5117 presents a significant bit of potential revenue for the fast-growing CRO, which has augmented its traditional offerings with a few risk-sharing drug development deals. WuXi's long-stated goal is to become the go-to partner for any drugmaker looking to break into the Chinese market, and its relationship with AstraZeneca could light the way for more collaborations, CEO Ge Li said.

"This initiative showcases WuXi's capabilities as a gateway for developing novel biologics in China," Li said in a statement.

Meanwhile, the CRO is forecasting 2015 revenue between $790 million and $800 million, good for 18% annual growth at midpoint. To get there, WuXi is planning to spend up to $200 million on capital projects, nearly double last year's budget, building new manufacturing outposts in China and expanding the company's genomics heft with new lab capacity.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库